Makale detayı · 2024
Stereotactic body radiotherapy results for de-novo extracranial oligometastatic cancer patients
Reports of Practical Oncology and Radiotherapy
- Yıl
- 2024
- ISSN
1507-1367- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
İngilizce (OpenAlex)
Background: The aim of study was to evaluate the oncological results of stereotactic body radiotherapy (SBRT) in de-novo oligometastatic (dOM) disease. Materials and methods: Hospitals were analyzed retrospectively. The endpoints of the study were overall survival (OS) and disease free survival (DFS). Results: 84 patients with treated between 08.06.2019-15.11.2022 were analyzed. The median follow up was 26 (range 6-219) months. dOM subgroups were as follows: 37 (44.0%) synchronous dOM (sdOM); 31 (37%) metachronous oligorecurrence (mdOR) and 16 (19.0%) metachronous oligoprogression (mdOP). Grade 1 acute side effects (ASE) were observed in only 1 patient and no grade ≥ 2 a ASE were observed. Progression was observed in 45 (53.6%) of the patients. The median DFS was 8 (range 1-32) mo, 1y DFS was 44.5%; 2y DFS was 26.2%. Significantly higher DFS was obtained in mdOR than sdOM and mdOP [p = 0.020; hazard ratio (HR): 1.6; 95% confidence interval (CI): 0.75-3.68%]. The relationship between response assessment after SBRT and DFS was significant (p < 0.001; HR: 4.8; 95% CI: 1.9-12.2). Twenty-nine (34.5%) patients were ex and 55 (65.5%) were alive. 1y OS was 75.6%; 2y OS -61.2%; 3y OS -57.4% and the median OS value has not yet been reached. Lower OS was observed in sdOM compared to mdOP and mdOR (p = 0.035, HR: 0.45; 95% CI: 0.21-0.96). The relationship between response assessment after SBRT and OS was significant (p = 0.017; HR: 6.6; 95% CI: 1.7-25.7). Conclusion: Higher DFS was observed in mdOR patients and lower OS was observed in sdOM patients. SBRT response in dOM patients may be a prognostic factor for DFS and OS.
Konular
- Brain Metastases and Treatment
- Management of metastatic bone disease
- Breast Cancer Treatment Studies
Birincil konu Brain Metastases and Treatment